Changes in the effectiveness of tobacco warning labels after implementation of the European Tobacco Products Directive – findings from the EUREST-PLUS ITC Europe surveys

GERMAN
CANCER RESEARCH CENTER
IN THE HELMHOLTZ ASSOCIATION

Research for a Life without Cancer

Sarah Kahnert^{1,2}, Pete Driezen, Tibor Demjén, Esteve Fernández, Paraskevi A. Katsaounou, Antigona C. Trofor, Krzysztof Przewoźniak, Geoffrey T. Fong, Constantine I. Vardavas, Ute Mons¹, on behalf of the EUREST-PLUS and ITC Project

Background

Tobacco product packaging is a key part of marketing efforts to make tobacco use appealing. In contrast, large, prominent health warnings are known to be effective in informing about the risks of smoking and motivating smokers to quit. In the European Union, since May 2016, the Tobacco Products Directive 2014/40/EU (TPD2), requires tobacco product packages to carry combined textual and pictorial warning labels (WL).

Methods

Data from a longitudinal sample of 6,011 adult smokers from Germany, Greece, Hungary, Poland, Romania, and Spain (ITC 6E Survey, EUREST-PLUS Project), were used. Self-reported perceived effectiveness of the WL was examined by means of smokers' ratings on warning salience, thoughts of harm and quitting, and forgoing of cigarettes. To examine changes in effectiveness of WL over time, Generalized Estimating Equations (GEE) models were computed.




Figure 1: Prevalence of having noticed warning labels (salience), thinking about the health risks of smoking (harm), wanting to quit (quitting), and being stopped from having a cigarette (forgoing) due to warning labels by survey wave (2016/2018) and by country; cross-sectional data

0.72 1.00 1.72	SALIENCE			HARM			QUITTING				FORGOING			
Wave 2 vs. Wave 1	N Events	aOR	(95 % CI)	N Events	aOR	(95 % CI)	N	Events	aOR	(95 % CI)	N	Events	aOR	(95 % CI)
Pooled sample	10884 6788	1.18	(1.03 to 1.35)	10814 6709	1.11	(0.99 to 1.25)	10762	5382	1.02	(0.90 to 1.16)	10813	1743	1.11	(0.93 to 1.32)
Germany	1711 946	1.10	(0.79 to 1.53)	1713 900	1.01	(0.81 to 1.26)	1711	693	1.10	(0.90 to 1.34)	1713	161	1.05	(0.74 to 1.49)
Greece	1892 875	1.07	(0.72 to 1.58)	1893 1269	1.33	(0.93 to 1.91)	1893	969	1.06	(0.74 to 1.53)	1892	268	1.20	(0.80 to 1.80)
Hungary	1893 984	1.43	(1.05 to 1.96)	1875 1093	0.86	(0.64 to 1.15)	1872	835	0.74	(0.52 to 1.06)	1879	323	0.78	(0.47 to 1.31)
Poland	1745 1516	1.58	(1.06 to 2.36)	1720 1109	1.34	(0.96 to 1.88)	1716	985	1.11	(0.82 to 1.50)	1710	359	0.81	(0.53 to 1.24)
Romania	1819 1351	1.50	(1.12 to 2.03)	1799 1178	1.04	(0.84 to 1.28)	1791	1052	1.03	(0.80 to 1.32)	1813	298	1.30	(0.86 to 1.97)
Spain	1824 1116	0.82	(0.62 to 1.08)	1814 1160	1.17	(0.90 to 1.54)	1779	848	1.14	(0.79 to 1.64)	1806	334	1.72	(1.14 to 2.60)

Figure 2: Results of GEE models estimating the change between survey waves (2016/2018) for having noticed warning labels (salience), thinking about health risks (harm), wanting to quit (quitting), and being stopped from having a cigarette (forgoing) due to warning labels in the pooled sample and by country; longitudinal adjusted Odds Ratios (aOR) are presented

Results

The effectiveness of the EU-standardized WL varied by country and tended to reflect the extent of their change of appearance. In the pooled sample, the warning labels' effectiveness increased significantly over time in terms of salience (adjusted OR = 1.18; 95%-CI: 1.03 to 1.35), while cognitive and behavioural reactions did not show clear increases. Generally, among women, more highly educated smokers and less addicted smokers, the effectiveness of warning labels tended to be higher.

Conclusions

We found an increase in salience, but no clear increases for cognitive and behavioural reactions to the new warning labels as required by the TPD2. While it is likely that our study underestimated the impact

of the new pictorial warning labels, it provides evidence that health messages on tobacco packaging are more salient when supported by large pictures.

Funding

The EUREST-PLUS project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 681109 (C.I.V.) and the University of Waterloo (G.T. Fong). Additional support was provided to the University of Waterloo by the Canadian Institutes of Health Research (FDN-148477). For more information on the project please visit: https://itcproject.org/projects/6-european-country-project-eurest-plus.